385 related articles for article (PubMed ID: 2453619)
1. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors.
Ozols RF; Ihde DC; Linehan WM; Jacob J; Ostchega Y; Young RC
J Clin Oncol; 1988 Jun; 6(6):1031-40. PubMed ID: 2453619
[TBL] [Abstract][Full Text] [Related]
2. Treatment of poor prognosis germ cell tumours with high dose cisplatin regimens.
Ozols RF
Int J Androl; 1987 Feb; 10(1):291-300. PubMed ID: 2438222
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen) in malignant nondysgerminomatous germ-cell tumors of the ovary.
Culine S; Kattan J; Lhomme C; Duvillard P; Michel G; Castaigne D; Leclere J; Pico J; Droz JP
Gynecol Oncol; 1994 Jul; 54(1):47-53. PubMed ID: 7517380
[TBL] [Abstract][Full Text] [Related]
4. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.
Williams SD; Birch R; Einhorn LH; Irwin L; Greco FA; Loehrer PJ
N Engl J Med; 1987 Jun; 316(23):1435-40. PubMed ID: 2437455
[TBL] [Abstract][Full Text] [Related]
5. Treatment of poor prognosis nonseminomatous testicular cancer with a "high-dose" platinum combination chemotherapy regimen.
Ozols RF; Deisseroth AB; Javadpour N; Barlock A; Messerschmidt GL; Young RC
Cancer; 1983 May; 51(10):1803-7. PubMed ID: 6187426
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.
Bosl GJ; Geller NL; Bajorin D; Leitner SP; Yagoda A; Golbey RB; Scher H; Vogelzang NJ; Auman J; Carey R
J Clin Oncol; 1988 Aug; 6(8):1231-8. PubMed ID: 2457657
[TBL] [Abstract][Full Text] [Related]
7. High-risk germ cell tumors in men. High response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide.
Blayney DW; Goldberg DA; Leong LA; Margolin KA; Burke JS; Doroshow JH
Cancer; 1993 Apr; 71(7):2351-7. PubMed ID: 7680946
[TBL] [Abstract][Full Text] [Related]
8. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial.
Fizazi K; Do KA; Wang X; Finn L; Logothetis CJ; Amato RJ
Ann Oncol; 2002 Jan; 13(1):125-34. PubMed ID: 11863094
[TBL] [Abstract][Full Text] [Related]
9. A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: role of maintenance and long-term follow-up.
Levi JA; Thomson D; Sandeman T; Tattersall M; Raghavan D; Byrne M; Gill G; Harvey V; Burns I; Snyder R
J Clin Oncol; 1988 Jul; 6(7):1154-60. PubMed ID: 2455778
[TBL] [Abstract][Full Text] [Related]
10. Vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum for advanced germ cell testis tumors: Brazilian experience.
Srougi M; Simon SD; de Góes GM
J Urol; 1985 Jul; 134(1):65-9. PubMed ID: 2409300
[TBL] [Abstract][Full Text] [Related]
11. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study.
Wozniak AJ; Samson MK; Shah NT; Crawford ED; Ford CD; Altman SJ; Stephens RL; Natale RB; Bouroncle BA; Blumenstein BA
J Clin Oncol; 1991 Jan; 9(1):70-6. PubMed ID: 1702148
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol.
Einhorn LH; Williams SD; Loehrer PJ; Birch R; Drasga R; Omura G; Greco FA
J Clin Oncol; 1989 Mar; 7(3):387-91. PubMed ID: 2465391
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
Grimison PS; Stockler MR; Thomson DB; Olver IN; Harvey VJ; Gebski VJ; Lewis CR; Levi JA; Boyer MJ; Gurney H; Craft P; Boland AL; Simes RJ; Toner GC
J Natl Cancer Inst; 2010 Aug; 102(16):1253-62. PubMed ID: 20631341
[TBL] [Abstract][Full Text] [Related]
15. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.
Kaye SB; Mead GM; Fossa S; Cullen M; deWit R; Bodrogi I; van Groeningen C; Sylvester R; Collette L; Stenning S; De Prijck L; Lallemand E; deMulder P
J Clin Oncol; 1998 Feb; 16(2):692-701. PubMed ID: 9469359
[TBL] [Abstract][Full Text] [Related]
16. Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study.
Tscherry G; Jacky E; Jost LM; Stahel RA
Oncology; 2000 Aug; 59(2):110-7. PubMed ID: 10971168
[TBL] [Abstract][Full Text] [Related]
17. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol.
Nichols CR; Williams SD; Loehrer PJ; Greco FA; Crawford ED; Weetlaufer J; Miller ME; Bartolucci A; Schacter L; Einhorn LH
J Clin Oncol; 1991 Jul; 9(7):1163-72. PubMed ID: 1710655
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
19. Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors.
Culine S; Théodore C; Bekradda M; Farhat F; Terrier-Lacombe MJ; Droz JP
Am J Clin Oncol; 1997 Apr; 20(2):184-8. PubMed ID: 9124197
[TBL] [Abstract][Full Text] [Related]
20. Sequential trials of cisplatin, vinblastine, and bleomycin and etoposide and cisplatin in disseminated nonseminomatous germ cell tumors of the testis with a good prognosis at a single institution.
Germá JR; Sagarra AF; Izquierdo MA; Seguí MA
Cancer; 1993 Feb; 71(3):796-803. PubMed ID: 7679314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
